Vendor comparison · 2026
Tesofensine vendors: 2 compared on COAs and price
MetabolicAlso known as NS2330
Evidence tier
Moderate published literature
56 publications over 19 years · trials not yet curated
- Vendors carrying it
- 2
- 1 with a listed price
- Vendors with checkable COAs
- 1
- 1 publish any certificate
- Lots tested
- 1
- 1 naming a checkable lab
- Independent assays
- 0
- none on file yet
- Newest assay
- 8 Jul 2026
- oldest 8 Jul 2026
- Laboratories named
- 1
- most often ILS Laboratories
- Median label gap
- 4.0%
- 100% of lots within 5% of label
- Median purity
- 99.79%
- 1 of 1 lots at 99% or above
- Lowest price per mg
- $278.00
- peer median $278.00
- Publications located
- 56
- researched since 2007
Source: PepIndex, an independent index of research-peptide vendors. No vendor can pay for a rank, every score is computed by a published formula, and every figure links to the document it was read from.
Next Gen Peptides has the most checkable Tesofensine testing in this index: 1 lot assayed by ILS Laboratories, the newest on 8 Jul 2026. The lowest listed price is $278.00 per mg at Modern Aminos, against a peer median of $278.00. 2 vendors carrying Tesofensine are compared below. 1 publish at least one certificate naming a checkable laboratory, 1 lot record is on file, and none is an independently commissioned assay. Figures are PepIndex's own: it is an independent index of research-peptide vendors, no vendor can pay for a rank, and each figure links to the certificate it was read from.
Every vendor carrying Tesofensine
| # | Vendor | Score here | Price / mg | Lots | Newest test | Laboratory | Mean purity | Label gap | Reports |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Next Gen PeptidesISO/IEC 17025 | 93.697% | — | 1 / 1 | ILS Laboratories | 99.8% | 4.0% | ||
| 2 | Modern AminosISO/IEC 17025COAs need an account | 80.997% | $278.00 (100%) | 0 | — | — | — | — | no reportVisit site |
Independent assays
No independently commissioned assay of Tesofensine is on file. All 1 records below were published by the vendor that sells the product, naming the laboratory shown. PepIndex does not yet commission its own assays, so nothing on this page establishes what is in a vial beyond the vendor’s own certificate. A record moves into this section the moment an assay commissioned by anyone other than the seller is indexed.
What the certificates show
1 of 1 lots at 99% or above; median 99.79%.
| Range | lots |
|---|---|
| <95% | 0 |
| 95–97% | 0 |
| 97–98% | 0 |
| 98–99% | 0 |
| 99–99.5% | 0 |
| ≥99.5% | 1 |
100% of lots within 5% of the labelled mass; median gap 4.0%.
| Range | lots |
|---|---|
| ≤2% | 0 |
| 2–5% | 1 |
| 5–10% | 0 |
| 10–20% | 0 |
| >20% | 0 |
1 vendors, $278.00 to $278.00; median $278.00.
| Range | vendors |
|---|---|
| $278.00 | 1 |
Purity and mass are read from each certificate as published; the label gap is |labeled − assayed| ÷ labeled. Every value behind these bars is in the certificate table below.
Laboratories used
| Laboratory | Lots | Vendors | Share | Verify |
|---|---|---|---|---|
| ILS LaboratoriesUS | 1 | 1 | 100% | Public lookup |
Every certificate record
| Vendor | Lot | Tested | Lab | Labeled | Assayed | Discrepancy | Purity | Report |
|---|---|---|---|---|---|---|---|---|
 Next Gen Peptides | TECAP02 | ILS Laboratories | 0.5 mg | 0.52 mg | 4.0% | 99.8% | Vendor-published |
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 2007 — 19 years of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
56 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
Mean assayed purity 99.8% across 1 certificate
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
single lot on record, mean label deviation 4.0%
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
2 of 2 listing vendors publish an accessible certificate policy
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
1 of 1 certificate from a recognised independent lab
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is Tesofensine?
A triple monoamine-reuptake inhibitor investigated clinically for weight management. It is not an approved medicine.
Studied in published research for obesity and weight management.
Regulatory status
Tesofensine is an investigational compound in clinical development and is not an approved medicine in the United States, United Kingdom or European Union. Products listed here are labeled by their vendors for laboratory research use only.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
PepIndex records the size and shape of the published research footprint only. It does not evaluate or summarise clinical significance, does not describe administration, and nothing here is a claim of safety or efficacy.
- Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity — Current opinion in investigational drugs (London, England : 2000) (2009)
Peer-reviewed article indexed in PubMed, published in Current opinion in investigational drugs (London, England : 2000) (2009).
- Tesofensine, a novel antiobesity drug, silences GABAergic hypothalamic neurons — PloS one (2024)
Peer-reviewed article indexed in PubMed, published in PloS one (2024).
- Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease — Obesity (Silver Spring, Md.) (2008)
Peer-reviewed article indexed in PubMed, published in Obesity (Silver Spring, Md.) (2008).
- Tesofensine and weight loss — Lancet (London, England) (2009)
Peer-reviewed article indexed in PubMed, published in Lancet (London, England) (2009).
- Tesofensine and weight loss — Lancet (London, England) (2009)
Peer-reviewed article indexed in PubMed, published in Lancet (London, England) (2009).
- Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat — Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology (2010)
Peer-reviewed article indexed in PubMed, published in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology (2010).
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.